Brad H. Rovin

1989–2025 年に発表

182
論文数
33,266
被引用数
89
h 指数
174
i10 指数

被引用数

Brad H. Rovin の年別被引用数1960 年: 被引用 1 件1980 年: 被引用 1 件1981 年: 被引用 1 件1984 年: 被引用 1 件1986 年: 被引用 1 件1989 年: 被引用 1 件1991 年: 被引用 2 件1992 年: 被引用 3 件1993 年: 被引用 7 件1994 年: 被引用 15 件1995 年: 被引用 10 件1996 年: 被引用 19 件1997 年: 被引用 24 件1998 年: 被引用 27 件1999 年: 被引用 28 件2000 年: 被引用 35 件2001 年: 被引用 32 件2002 年: 被引用 27 件2003 年: 被引用 29 件2004 年: 被引用 50 件2005 年: 被引用 74 件2006 年: 被引用 90 件2007 年: 被引用 117 件2008 年: 被引用 139 件2009 年: 被引用 138 件2010 年: 被引用 126 件2011 年: 被引用 100 件2012 年: 被引用 118 件2013 年: 被引用 141 件2014 年: 被引用 102 件2015 年: 被引用 172 件2016 年: 被引用 181 件2017 年: 被引用 145 件2018 年: 被引用 152 件2019 年: 被引用 663 件2020 年: 被引用 806 件2021 年: 被引用 1,002 件2022 年: 被引用 1,115 件2023 年: 被引用 1,148 件2024 年: 被引用 2,030 件2025 年: 被引用 1,045 件2026 年: 被引用 21 件1961〜1979 年は被引用が無いため表示していません1982〜1983 年は被引用が無いため表示していません1985 年は被引用が無いため表示していません1987〜1988 年は被引用が無いため表示していません1990 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,716 件、この内訳の 23.2%中国: 引用元論文 1,357 件、この内訳の 11.6%イギリス: 引用元論文 843 件、この内訳の 7.2%ドイツ: 引用元論文 622 件、この内訳の 5.3%イタリア: 引用元論文 595 件、この内訳の 5.1%フランス: 引用元論文 427 件、この内訳の 3.6%カナダ: 引用元論文 425 件、この内訳の 3.6%日本: 引用元論文 416 件、この内訳の 3.6%スペイン: 引用元論文 364 件、この内訳の 3.1%オランダ: 引用元論文 353 件、この内訳の 3%オーストラリア: 引用元論文 322 件、この内訳の 2.8%スウェーデン: 引用元論文 227 件、この内訳の 1.9%
0%23.2%その他 26%

分野

  • Medicine72%
  • Biochemistry, Genetics and Molecular Biology15.7%
  • Immunology and Microbiology7.6%
  • Neuroscience0.8%
  • Agricultural and Biological Sciences0.6%
  • Engineering0.5%
  • その他2.8%

トピック

  • Renal Diseases and Glomerulopathies8%
  • Systemic Lupus Erythematosus Research7.1%
  • Chronic Kidney Disease and Diabetes5.7%
  • Vasculitis and related conditions3%
  • T-cell and B-cell Immunology2%
  • Dialysis and Renal Disease Management1.8%
  • その他72.4%

共著者

全論文

検索で開く
  1. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Kidney International 2021 被引用: 2,416

  2. An atlas of healthy and injured cell states and niches in the human kidney

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sylvia E. Rosas, F. Perry Wilson, Paul M. Palevsky, Krzysztof Kiryluk, John R. Sedor, Robert D. Toto, Chirag R. Parikh, Eric H. Kim, Rahul Satija, Anna Greka, Evan Z. Macosko, Peter V. Kharchenko, Joseph P. Gaut, Jeffrey B. Hodgin, Richard A. Knight, Stewart H. Lecker, Isaac E. Stillman, Afolarin Amodu, Titlayo Ilori, Shana Maikhor, Insa M. Schmidt, Gearoid M. McMahon, Astrid Weins, Nir Hacohen, Lakeshia Bush, Agustin Gonzalez‐Vicente, Jonathan J. Taliercio, John O’Toole, Emilio D. Poggio, Leslie Cooperman, Stacey E. Jolly, Leal Herlitz, Jane Nguyen, Ellen L. Palmer, Dianna Sendrey, Kassandra Spates-Harden, Paul S. Appelbaum, Jonathan Barasch, Andrew S. Bomback, Vivette D. D’Agati, Karla Mehl, Pietro A. Canetta, Ning Shang, Olivia Balderes, Satoru Kudose, Laura Barisoni, Theodore Alexandrov, Ying‐Hua Cheng, Kenneth W. Dunn, Katherine J. Kelly, Timothy A. Sutton, Yumeng Wen, Celia P. Corona-Villalobos, Steven Menez, Avi Z. Rosenberg, Mohammed Atta, Camille Johansen, Jennifer K. Sun, Neil Roy, Mark Williams, Evren U. Azeloglu, Cijang He, Ravi Iyengar, Jens Hansen, Yuguang Xiong, Brad H. Rovin, Samir V. Parikh, Sethu M. Madhavan, Christopher Anderton, Ljiljana Paša‐Tolić ほか 70 名 - Nature 2023 被引用: 693

  3. Differential Diagnosis of Glomerular Disease: A Systematic and Inclusive Approach

    著者: , , , , - American Journal of Nephrology 2013 被引用: 4,380

  4. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis

    著者: , , , , , , , , , , , , , , , , - New England Journal of Medicine 2020 被引用: 973

  5. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial

    著者: , , , , , , , , , , , , - Annals of the Rheumatic Diseases 2022 被引用: 438

  6. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Martin Howell, Marcello Tonelli, Michael Cheung, Amy Earley, Jürgen Floege - Kidney International 2021 被引用: 791

  7. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study

    著者: , , , , , , , , , , , - Arthritis & Rheumatism 2012 被引用: 1,437

  8. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

    著者: , , , , , , , , , , , , , - The Lancet 2021 被引用: 593

  9. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Muh Geot Wong, Vlado Perkovic, Isabella Abbasciano, Catarina Abrantes, Simone Accarino, Sharon G. Adler, Annika Adoberg, Rouzbeh Afsari, Syeda B. Ahmad, Jafar Ahmed, Wooin Ahn, Bamidele Ajayi, Dariusz Aksamit, Saif Al‐Chalabi, É. Alamartine, Bassam Alchi, Mohammad Ali, Roberta Aliotta, Salem Almaani, Catarina Almeida, Edgar Almeida, Francisco de la Prada Álvarez, Patrícia Marques‐Alves, Francesca Annese, Gerald B. Appel, Gerald Appel, Maria Arena, Marta Calvo Arevalo, Dariush Arfaania, Carlos Arias, Emma Calatayud Aristoy, Eglė Ašakienė, Sarah Ashley, Ali Assefi, Alba Atenza, Asta Auerbach, Hanna Augustyniak‐Bartosik, Hanna Augustyniak-Bartosik, Jonathan Ayling-Smith, Isabelle Ayoub, Isabelle Ayoub, Rocco Baccaro, Asha Bailey, Bruce Baker, Saravanan Balamuthusamy, José Ballarín, Rui Barata, Jerko Barbić, Dunja Barisic, Jonathan Barratt, José C. Barreto, Clara Barrios, Mirco Belingheri, Anna Benesova, Ana Ávila Bernabéu, Wanja Bernhardt, Shamik Bhadra, Luigi Biancone, Anne Blanchard, Elena Boaglio, Davide Bolignano, Andrew S. Bomback, Gustavo Andres Useche Bonilla, M Bordoli, Bhadran Bose, Neil Boudville, Donald Brandon, Donald Brandon, Karen Brown, C Broyet ほか 634 名 - The Lancet 2023 被引用: 267

  10. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial

    著者: , , , , , , , , , , , - The Lancet 2023 被引用: 289

  11. KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS

    著者: , , , , , - Kidney International 2024 被引用: 418

  12. Lupus nephritis is linked to disease-activity associated expansions and immunity to a gut commensal

    著者: , , , , , , , , , - Annals of the Rheumatic Diseases 2019 被引用: 433

  13. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jay Radhakrishnan, Heather N. Reich, Samir V. Parikh, Debbie S. Gipson, Dominic K. Lee, Bruno R. da Costa, Peter Jüni, Daniel Cattran - New England Journal of Medicine 2019 被引用: 600

  14. Update on Lupus Nephritis: Core Curriculum 2020

    著者: , , , - American Journal of Kidney Diseases 2020 被引用: 489

  15. Update on Lupus Nephritis

    著者: , , - Clinical Journal of the American Society of Nephrology 2016 被引用: 918

  16. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mai Rosenberg, Brad H. Rovin, Sydney Tang, Vladmir Tesar, Muh Geot Wong, Bhadran Bose, Muralikrishna Gangadharan, Stephen P. McDonald, Chen Au Peh, Sadia Jahan, Chii Yeap, Philip A. Clayton, Georgina Irish, Nikhil Thyagarajan, Peter Hollett, Rathika Krishnasamy, Robert J. Carroll, Shilpanjali Jesudason, Susan Crail, Toby Coates, Jane Waugh, Euan Noble, Kumaradevan Mahadevan, Victoria Campbell, Tania Salehi, Wai H. Lim, Neil Boudville, Aron Chakera, Doris Chan, Anoushka Krishnan, Yusuf Eqbal, Alastair Gillies, Eswari Vilayur, Thida Maung Myint, Nicholas A. Gray, Jane Waugh, Euan Noble, Melissa S Cheetham, Yusuf Eqbal, Peter Hollett, Rathika Krishnasamy, Kumaradevan Mahadevan, Victoria Campbell, Carol A. Pollock, Bruce A. Cooper, Amanda Mather, Sarah Roxburgh, Yvonne Shen, Stefanie Stangenberg, Amanda Siriwardana, Emma O’Lone, Susan Wan, Brendon L. Neuen, Jeffrey T. Ha, Dana Kim, Lauren Heath, Arunima Jain, Elaine Phua, Li Yan, M. W. Gallagher, Meg Jardine, Angus Ritchie, Mona Razavian, Celine Foote, Roger Wyndham, Shaundeep Sen, Zoltán Endre, Jonathan Erlich, Mangalee Fernando, Kenneth Yong ほか 631 名 - The Lancet 2023 被引用: 215

  17. Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy

    著者: , , , , , , , , , , , , , , , , - Clinical Journal of the American Society of Nephrology 2019 被引用: 288

  18. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Maria Paula Dionisi, Jessica Ryan, Nigel D. Toussaint, Grant Luxton, Chen Au Peh, Vicki Levidiotis, Ross S. Francis, Richard Phoon, Elena Fedosiuk, D.M. Toropilov Toropilov, R. E. Yakubtsevich, Elena Mikhailova, Christophe Bovy, Nathalie Demoulin, Jean‐Michel Hougardy, Bart Maes, Marijn M. Speeckaert, Louis‐Philippe Laurin, Sean Barbour, Mélanie Masse, Michelle Hladunewich, Heather N. Reich, Serge Cournoyer, Karthik Tennankore, Sean Barbour, Jicheng Lv, Zhangsuo Liu, Caili Wang, Shaomei Li, Qun Luo, Zhaohui Ni, Tiekun Yan, Ping Fu, Hong Cheng, Bi‐Cheng Liu, Wanhong Lu, Jianqin Wang, Qinkai Chen, D. Wang, Zuying Xiong, Menghua Chen, Yan Xu, Jiali Wei, Pearl Pai, Lianhua Chen, Jitka Řehořová, Dita Maixnerová, Roman Šafránek, Ivan Rychlík, M Hrubý, Satu Mäkelä, Kati Vääräniemi, Fernanda Ortiz, É. Alamartine, Maïté Daroux, C. Cartery, François Vrtovsnik, Jean‐Emmanuel Serre, Eleni Stamellou, Volker Vielhauer, Christian Hugo, Klemens Budde, Britta Otte, Martin Nitschke, Evangelia Ntounousi, Ioannis Boletis, Αikaterini Papagianni, Dimitrios Goumenos, Kostas Stylianou, Synodi Zermpala ほか 59 名 - Kidney International 2022 被引用: 215

  19. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis

    著者: , , , , , , , , , , - Annals of the Rheumatic Diseases 2022 被引用: 194

  20. A reference tissue atlas for the human kidney

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kun Zhang, Jonathan Himmelfarb, Brad H. Rovin, Tarek M. El‐Achkar, Zoltán Lászik, John Cijiang He, Pierre C. Dagher, M. Todd Valerius, Sanjay Jain, Lisa M. Satlin, Olga G. Troyanskaya, Matthias Kretzler, Ravi Iyengar, Evren U. Azeloglu, Kidney Precision Medicine Project - Science Advances 2022 被引用: 172

  21. Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy

    著者: , , , , , , , , , , , , , , , - Kidney International 2023 被引用: 121

  22. A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction

    著者: , , , , , , , , , , , , , , , , , - Journal of the American Society of Nephrology 2016 被引用: 288

  23. A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis

    著者: , , , , , , , , , , , , - Kidney International 2021 被引用: 198

  24. Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2023 被引用: 105